© 2022 Sema4 OpCo, Inc. All rights reserved.
August 26th, 2022
Who We Are
A Patient-centered Health Intelligence Company Advancing Healthcare Through Data-driven Insights
Sema4 is transforming healthcare by using artificial intelligence to enable the delivery of precision medicine as the standard of care.
Centrellis®:
Our Health Data Engine
Our unique analytics platform, Centrellis, enables us to transform standard of care insights by reconstructing longitudinal patient journeys, derive population health insights, and deliver AI-powered disease models.
Robust
Research
Sema4’s accomplished research team includes world leaders in data science, machine learning, network modeling, and genomics. We’ve published more than 180 peer-reviewed papers and are committed to providing science-driven solutions to the most pressing medical needs.
Our areas of focus
Women’s Health
Our Sema4 Elements™ portfolio of information-driven genomic solutions, digital tools, and services enables providers to treat patients holistically during their reproductive and generational health journey, from preconception planning to hereditary cancer testing.
Hereditary Cancer
Our hereditary cancer testing can provide actionable insights to guide clinical care decisions and better prevent, detect, or treat certain cancers.
Biopharma
Sema4 offers an extensive portfolio of health information solutions, including pre-clinical and clinical trial support, analytics for actionable insights, and advanced sequencing services, to drive informed decision-making across the drug discovery, development, and commercialization lifecycle.
Latest News
August 15th, 2022
Sema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial Results
August 15th, 2022
Sema4 Announces Changes to its Research & Development Leadership
Featured In
Awards & Recognition
Fast Company
List of the World’s
Most Innovative Companies
Most Innovative Companies
Forbes
List of America’s Best Startup Employers
Gartner
Cool Vendor in Healthcare Technology
CB Insights
Digital Health 150
